Life Sciences: Pricing and Market Access Strategy

Pricing & Market Access Strategy

Pricing and market access decisions are critical levers that make the difference between maximizing the value of a given product and leaving significant money on the table. Manufacturers who want to develop successful pricing and market access strategies must navigate the complex and evolving interactions between customers and products.

Strategic support throughout the lifecycle

CRA can assist with all elements of pricing, value and access strategy development.

Early development
  • Market, competitor and payer landscaping
  • Payer insights on go-no-go decision making and investment requirements
  • Payer needs assessment
  • P&MA achievable
  • Evidence requirements
Late development
  • Payer value drivers and P&MA positioning strategies
  • Payer value proposition and value message development
  • Evidence generation strategies
  • Payer value and evidence packs
  • P&MA strategy development
  • Launch pricing strategies
  • Contracting strategies
  • Competitor strategies
  • Launch pricing strategies
  • Policy strategies/initiatives
Life cycle & LOE
  • Life cycle management strategies – new indications, markets, geographies
  • Competitor response strategies
  • Price/access/uptake benchmarking and assessments
  • LOE strategies

Sample engagements

Pricing and contracting strategy for rare disease launch
Assessed risk of global tender contagion
Pricing strategy for fixed-dose combination analogues
Market access strategy for regional execution
Customer segmentation and targeting strategy

Our life sciences practice is made up of 185 consultants that blend decades of global business experience with an extensive understanding of life sciences.

Meet our senior team >